FibroGen Announces Topline Data from Phase 3 LELANTOS-2 Study
FibroGen has announced topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, their investigational anti-fibrotic monoclonal antibody, for ambulatory patients with Duchenne muscular dystrophy. Although generally safe and well tolerated, pamrevlumab did not meet…Learn More